Sibanye Gold Ltd (ADR) (NYSE:SBGL), Coherus Biosciences Inc (NASDAQ:CHRS)

At recent session, the prices were hovering between $14.05 and $15.875.

Several brokerages recently commented on CHRS. Robert W. Baird analysts stated on 19/10/2016 that they launched coverage on this stock with Outperform rating. Until then, the company enjoys exclusivity and market domination. Panagora Asset Mngmt stated it has 0.01% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS).

Analyst rating about Coherus Biosciences, Inc. Vanguard Group Inc. now owns 2,209,244 shares of the biotechnology company's stock valued at $46,726,000 after buying an additional 1,039,402 shares during the last quarter.

Analysts await Magellan Health Inc (NASDAQ:MGLN) to report earnings on August, 4. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 8, 2017 and its future periodic reports to be filed with the Securities and Exchange Commission. The company has market cap of $733.67 million. The company presently has an average rating of "Buy" and a consensus target price of $40.63. Vanguard Group Inc. boosted its position in Coherus BioSciences by 88.8% in the first quarter. On average, equities research analysts expect that Coherus BioSciences will post ($5.13) EPS for the current year. Fmr Ltd Limited Liability Company reported 0.02% in Coherus Biosciences Inc (NASDAQ:CHRS). TIAA CREF Investment Management LLC now owns 586,875 shares of the biotechnology company's stock valued at $12,412,000 after buying an additional 308,332 shares during the last quarter.

The Food and Drug Administration has rejected Coherus BioSciences' biosimilar of Amgen's cancer drug Neulasta (pegfilgrastim), sending shares in the biosimilars-focused company tumbling 24% Monday. In a transaction dated April 03, 2017, the shares were put up for sale at an average price of $20.73, raking in a sum of $234,933. Here's a quick look at what's moving shares of GE, CHRS, and FB. Zacks Investment Research cut Coherus Biosciences from a "buy" rating to a "hold" rating in a research note on Thursday, February 16th. Rock Springs Capital Management LP boosted its stake in shares of Coherus Biosciences by 16.9% in the third quarter. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. AXA boosted its stake in shares of Coherus Biosciences by 19.1% in the first quarter. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of U.S. and worldwide trademark and copyright laws. Hedge funds and other institutional investors own 64.52% of the company's stock.

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Coherus BioSciences, a late-stage clinical biologics platform company, which engages in the development and commercializition of biosimilar therapeutics worldwide.

Coherus, which is developing various biosimilars, has also submitted an application to market its Neulasta copy in Europe.

Like this


27 June 2017
What's Ahead for Arista Networks Inc (ANET) After Achieving 52-Week High?
It develops, markets and sells cloud networking solutions, which consist of its Gigabit Ethernet switches and related software. On average, equities analysts expect that Arista Networks will post $3.95 earnings per share for the current fiscal year.

27 June 2017
Fatherhood is my sole goal : Shayne Ward
And that's despite the awkward love triangle. What I appreciate from Coronation Street is. Let us know over on Facebook and Twitter.

27 June 2017
What's Propelling InterXion Holding NV (INXN) to Reach 52-Week High?
Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. The stock of InterXion Holding NV (NYSE:INXN) earned "Overweight" rating by Barclays Capital on Monday, September 28.

27 June 2017
USANA Health Sciences, Inc. (USNA) Director Sells $2599600.00 in Stock
Out of 2 Wall Street analysts rating Northern Trust, 1 give it "Buy", 0 "Sell" rating , while 1 recommend "Hold". The stock of CGI Group Inc (NYSE:GIB) earned "Buy" rating by Desjardins Securities on Friday, May 27.

27 June 2017
Anthem Reaches $115M Data Breach Settlement
As part of the settlement, Anthem would also commit more money to improve its data security and encryption systems in the future. The company will also have to provide compensation to customers already enrolled in credit monitoring services.

27 June 2017
Anonymous believes NASA is poised to announce discovery of aliens
The video has made a big splash online - so big that NASA science chief Thomas Zurbuchen addressed the rumor today (June 26). Anonymous has released a video that has claimed that NASA is just about to announce the evidence of alien life .

27 June 2017
Tetra Tech, Inc. (TTEK) Cut to "Buy" at BidaskClub
On September 30 analysts at Loop Capital started covering the stock with an initial rating of "Buy" and a price target of $9.00. Tetra Tech, Inc is a provider of consulting, engineering, program management, construction management, and technical services.

27 June 2017
Cara Therapeutics, Inc. (NASDAQ:CARA) Experiencing Unusual Activity Mid-day
HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Cara Therapeutics in a report on Thursday. It worsened, as 42 investors sold WU shares while 211 reduced holdings. 7 funds opened positions while 17 raised stakes.

27 June 2017
AT&T Emails Can No Longer Be Used To Login To Yahoo
In order to continue accessing Yahoo services, account owners need to use email addresses aside from those provided by AT&T. Thankfully, that's not the case, as this is mostly about winding down the corporate deals prior to the acquisition.

27 June 2017
Will Georgia's 6th District do this all again in 2018?
Kathleen Rice (D-N.Y.) said Thursday on MSNBC's "Morning Joe" that the time for Pelosi's leadership has "come and gone". Pelosi told fellow House Democrats in a letter Wednesday, "The House was in play before the Georgia race".